Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fomepizole oral - Horizon Therapeutics plc

Drug Profile

Fomepizole oral - Horizon Therapeutics plc

Alternative Names: 4-Methylpyrazole; 4-MP - Horizon Therapeutics plc; Convivia

Latest Information Update: 06 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Convivia
  • Developer Horizon Therapeutics plc
  • Class Antidotes; Pyrazoles; Small molecules
  • Mechanism of Action Alcohol dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Metabolic disorders

Most Recent Events

  • 02 May 2019 Horizon Pharma is now called Horizon Therapeutics plc
  • 01 Sep 2015 Clinical development is ongoing in the USA
  • 12 Aug 2014 Fomepizole oral is still in phase II development for Metabolic disorders

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top